Improving cancer outcomes through better cancer data in Poland
Journal Title: OncoReview - Year 2013, Vol 3, Issue 3
Abstract
Based on NFZ published aggregate data, the public spending on cancer care in Poland was 6.3 billion PLN in 2011 (or approximately 10% of total public health spending). Poland is one of the few large countries in the world that has two centralised and public data sources for cancer, namely the National Cancer Registry (NCR, pol. Krajowy Rejestr Nowotworów – KRN) and activity expenditure database run by the National Health Fund (NFZ,pol. Narodowy Fundusz Zdrowia). We show in our article that having a population-based registry and a complete treatment/clinical care dataset is a necessary condition to have a useful cancer strategy data set that can in turn lead to evidence based health policies in the area of cancer. Lack of audited and publicly available cancer data means that a coherent cancer strategy, assessing service provision and cost effectiveness of treatments and monitoring outcomes is, in our opinion, currently not possible in Poland. We postulate that Poland should create a task force to create cancer data strategy based on NCIN (National Cancer Intelligence Network) in the UK or Cancer Australia.
Authors and Affiliations
Margaret Gralinska, Sergiusz Nawrocki
Meeting the human. What can I get out of it?
Recently patients representatives are more often invited to oncological congresses. They would like to draw attention of the medical society to other than medical problems of people with cancer. Doctors should remember h...
Consensus statement on indications for the use of non-pegylated liposomal doxorubicin in patients with lymphomas and concomitant cardivascular diseases
Treatment of multiple superficial basal cell carcinomas with topical imiquimod
Basal cell carcinoma is the most common malignancy of man. The use of the topical imiquimod 5% cream offers a noninvasive, nonsurgical, and an effective option for the treatment of primary types superficial basal cell ca...
Angioplastyka wieńcowa oraz wymiana zastawki aortalnej u dwóch chorych ze szpiczakiem mnogim - opisy przypadków
Szpiczak mnogi jest schorzeniem hematologicznym charakteryzującym się klonalnym rozrostem atypowych plazmocytów, produkujących monoklonalną immunoglobulinę. Roczna zapadalność na niego w Europie wynosi ok. 4,5/100 000 os...
Antyproliferacyjne działanie analogów somatostatyny - przesłanie z badania PROMID